Clinical trial
Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With…
NCT00314977 · Radboud University Medical Center, Other · Completed
Key facts
| NCT number | NCT00314977 |
|---|---|
| Title | Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. |
| Official title | Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable and/or Locally Advanced Breast Cancer. The INTENS Study |
| Acronym | INTENS |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | Sanofi Industry Amgen |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Doxorubicin, Cyclophosphamide, Docetaxel |
| Enrollment | 200 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2009 |
| First posted | Apr 17, 2006 |
| Last update posted | Mar 18, 2010 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: